

## COMPANY OVERVIEW

By using the body's immune system, Anixa Biosciences is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.

## RECENT NEWS

### U.S. Department of Veterans Affairs and McGuire Research Institute Join Anixa Biosciences Cchek™ Prostate Cancer Study

Mar 25 2019, 7:00 AM EDT

### Anixa Biosciences Announces Notice of Allowance for Additional Cancer Detection Technology Patent

Mar 14 2019, 7:00 AM EDT

### Anixa Biosciences to Present Cchek™ Technology and Data at the Molecular Medicine Tri-Conference

Mar 4 2019, 7:00 AM EST

## STOCK OVERVIEW

Symbol	ANIX
Exchange	Nasdaq
Market Cap	89.11m
Last Price	\$4.54
52-Week Range	\$2.96 - \$6.86

03/25/2019 04:00 PM EDT

## INVESTOR RELATIONS

Mike Catelani  
Chief Operating Officer & Chief Financial Officer  
T: 408-708-9808

## MANAGEMENT TEAM

### Dr. Amit Kumar, Ph.D

Chairman, President & Chief Executive Officer

### Michael Catelani

Chief Operating Officer and Chief Financial Officer

### John Roop

Senior Vice President of Engineering

### Anthony Campisi

Vice President of Engineering

## ANIXA BIOSCIENCES, INC.

3150 Almaden Expressway  
Suite 250  
San Jose, CA 95118  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.